Company intelligence / Profile preview

Nucleis Radiopharmaceuticals

Liège, Belgium

Ownership: Private
Development stage: Other

Overview

Nucleis was a Belgian GMP-certified CDMO and manufacturer specializing in radiopharmaceuticals focused on PET diagnostics, offering tracer manufacturing and distribution across Benelux, France, Germany, Luxembourg, and the Netherlands. After its April 2025 acquisition by Curium, it expanded capabilities in oncology, neurology, and cardiology PET tracers.

Therapeutic areas: OncologyNeurologyCardiovascular
Modalities: RadiopharmaceuticalPET tracers
Industry: Contract Manufacturing Organization

Partnerships

University of LiègeCyclotron Research Centre

Beyond the preview

Go deeper on Nucleis Radiopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nucleis Radiopharmaceuticals.

Explore the full profile